STAAR's hyperopic ICLs (implantable contact lenses) enter Phase III trials:
This article was originally published in Clinica
STAAR Surgical is to begin Phase III trials of its implantable contact lenses for farsightedness. The expanded US study will include patients with hyperopia of 1.5 dioptres and will reduce the waiting time for implanting the second ICL in the same from six months to 45 days.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.